TARS

SEC source: 0001228684-26-000004 · wk-form4_1781640385.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

SEC source: 0001458643-26-000002 · wk-form4_1781640370.xml · derivative · entry 2

CHAUDHURI BHASKAR · CIK 0001458643 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,954 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F3 · derivative.expiration_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

SEC source: 0001458643-26-000002 · wk-form4_1781640370.xml · nonDerivative · entry 1

CHAUDHURI BHASKAR · CIK 0001458643 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,654

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

SEC source: 0001181186-26-000004 · wk-form4_1781640335.xml · derivative · entry 2

YARNO WENDY L · CIK 0001181186 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,954 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F3 · derivative.expiration_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

SEC source: 0001181186-26-000004 · wk-form4_1781640335.xml · nonDerivative · entry 1

YARNO WENDY L · CIK 0001181186 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,654

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

SEC source: 0001827722-26-000002 · wk-form4_1781640318.xml · derivative · entry 2

Goldberg Andrew D. · CIK 0001827722 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,954 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F3 · derivative.expiration_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

SEC source: 0001827722-26-000002 · wk-form4_1781640318.xml · nonDerivative · entry 1

Goldberg Andrew D. · CIK 0001827722 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,654

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

SEC source: 0001051578-26-000006 · wk-form4_1777407836.xml · derivative · entry 3

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,383 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: The RSUs vested in full on April 24, 2026, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs vested in full on April 24, 2026, subject to the Reporting Person's continuous service.

SEC source: 0001051578-26-000006 · wk-form4_1777407836.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,383

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

SEC source: 0001827584-26-000011 · wk-form4_1774386340.xml · nonDerivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,791

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001841401-26-000007 · wk-form4_1773961481.xml · nonDerivative · entry 3

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,959

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001839516-26-000009 · wk-form4_1773961495.xml · nonDerivative · entry 3

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,028

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827584-26-000009 · wk-form4_1773961468.xml · nonDerivative · entry 3

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,780

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001788542-26-000007 · wk-form4_1773961455.xml · nonDerivative · entry 3

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,480

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001842190-26-000007 · wk-form4_1773961442.xml · nonDerivative · entry 3

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,308

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001405253-26-000007 · wk-form4_1773961430.xml · nonDerivative · entry 3

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,316

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827672-26-000007 · wk-form4_1773961418.xml · nonDerivative · entry 3

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,421

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001841401-26-000007 · wk-form4_1773961481.xml · nonDerivative · entry 2

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,190

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001839516-26-000009 · wk-form4_1773961495.xml · nonDerivative · entry 2

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,202

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827584-26-000009 · wk-form4_1773961468.xml · nonDerivative · entry 2

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,369

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001788542-26-000007 · wk-form4_1773961455.xml · nonDerivative · entry 2

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,920

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001842190-26-000007 · wk-form4_1773961442.xml · nonDerivative · entry 2

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,698

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001405253-26-000007 · wk-form4_1773961430.xml · nonDerivative · entry 2

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,502

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827672-26-000007 · wk-form4_1773961418.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,385

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001841401-26-000007 · wk-form4_1773961481.xml · nonDerivative · entry 1

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,315

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001839516-26-000009 · wk-form4_1773961495.xml · nonDerivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,273

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827584-26-000009 · wk-form4_1773961468.xml · nonDerivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,979

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001788542-26-000007 · wk-form4_1773961455.xml · nonDerivative · entry 1

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,250

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001842190-26-000007 · wk-form4_1773961442.xml · nonDerivative · entry 1

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,077

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001405253-26-000007 · wk-form4_1773961430.xml · nonDerivative · entry 1

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,635

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001827672-26-000007 · wk-form4_1773961418.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,052

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001228684-26-000002 · wk-form4_1773864674.xml · nonDerivative · entry 3

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,332

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $69.68 to $69.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001228684-26-000002 · wk-form4_1773864674.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,825

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $68.64 to $69.63. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001228684-26-000002 · wk-form4_1773864674.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,203

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $67.60 to $68.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001827584-26-000007 · wk-form4_1773779723.xml · derivative · entry 6

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,067

Underlying: Common Stock · 5,022 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F7 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

F7 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001827584-26-000007 · wk-form4_1773779723.xml · derivative · entry 5

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,040

Underlying: Common Stock · 8,020 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001827584-26-000007 · wk-form4_1773779723.xml · derivative · entry 4

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,148

Underlying: Common Stock · 8,148 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001827584-26-000007 · wk-form4_1773779723.xml · derivative · entry 3

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,097 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

SEC source: 0001827584-26-000007 · wk-form4_1773779723.xml · nonDerivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,104

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

SEC source: 0001839516-26-000007 · wk-form4_1773780030.xml · derivative · entry 5

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,067

Underlying: Common Stock · 5,022 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F6 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

F6 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001839516-26-000007 · wk-form4_1773780030.xml · derivative · entry 4

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,351

Underlying: Common Stock · 7,176 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001839516-26-000007 · wk-form4_1773780030.xml · derivative · entry 3

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,249

Underlying: Common Stock · 7,248 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F4 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001839516-26-000007 · wk-form4_1773780030.xml · derivative · entry 2

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,463 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

F3 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

SEC source: 0001839516-26-000007 · wk-form4_1773780030.xml · nonDerivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,302

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

SEC source: 0001841401-26-000005 · wk-form4_1773779905.xml · derivative · entry 5

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,067

Underlying: Common Stock · 5,022 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F7 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

F7 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001841401-26-000005 · wk-form4_1773779905.xml · derivative · entry 4

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,351

Underlying: Common Stock · 7,176 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001841401-26-000005 · wk-form4_1773779905.xml · derivative · entry 3

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,249

Underlying: Common Stock · 7,248 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001841401-26-000005 · wk-form4_1773779905.xml · derivative · entry 2

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

SEC source: 0001841401-26-000005 · wk-form4_1773779905.xml · nonDerivative · entry 1

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,399

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F2 · balance_after: Includes 451 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025.

SEC source: 0001405253-26-000005 · wk-form4_1773779217.xml · derivative · entry 3

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,067

Underlying: Common Stock · 5,022 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

F4 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.